$1,318.00
This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and asset acquisition deals, a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
9 TREATMENT
9 Non-pharmacological therapy
9 Pharmacological therapy
11 EPIDEMIOLOGY
15 MARKETED DRUGS
21 PIPELINE DRUGS
27 RECENT EVENTS AND ANALYST OPINION
27 SPN-812 for ADHD (December 22, 2020)
28 ABV-1504 for ADHD (November 9, 2020)
29 SPN-812 for ADHD (November 9, 2020)
30 AR19 for ADHD (October 8, 2020)
31 AR19 for ADHD (October 6, 2020)
32 AR19 for ADHD (September 10, 2020)
34 KEY UPCOMING EVENTS
35 KEY REGULATORY EVENTS
35 Keeping Track: Supernus Requests Adult Indication For ADHD Drug Qelbree
35 Keeping Track: US FDA Clears Another Novel ADHD Drug; Submissions Blossom
35 Keeping Track: US FDA Approves Azstarys For ADHD
35 Noven Submits New Drug Application For Dextroamphetamine Transdermal System
35 Supernus Removes Reference To Lab Move In SPN-812 NDA
36 PROBABILITY OF SUCCESS
37 LICENSING AND ASSET ACQUISITION DEALS
37 With China CNS Plans, SK Biopharm Completes Strategy For Key Markets
38 REVENUE OPPORTUNITY
41 CLINICAL TRIAL LANDSCAPE
42 Sponsors by status
43 Sponsors by phase
45 BIBLIOGRAPHY
47 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in prevalent cases of ADHD, 2021–30
21 Figure 2: Overview of pipeline drugs for ADHD in the US
21 Figure 3: Pipeline drugs for ADHD, by company
22 Figure 4: Pipeline drugs for ADHD, by drug type
22 Figure 5: Pipeline drugs for ADHD, by classification
28 Figure 6: SPN-812 for ADHD (December 22, 2020): Phase III – P306 (Adults)
33 Figure 7: AR19 for ADHD (September 10, 2020): Phase III – AR19.004
34 Figure 8: Key upcoming events in ADHD
36 Figure 9: Probability of success in the ADHD pipeline
41 Figure 10: Clinical trials in ADHD
41 Figure 11: Top 10 drugs for clinical trials in ADHD
42 Figure 12: Top 10 companies for clinical trials in ADHD
42 Figure 13: Trial locations in ADHD
43 Figure 14: ADHD trials status
44 Figure 15: ADHD trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent cases of ADHD, 2021–30
14 Table 2: Prevalent cases of persistent ADHD in adults, 2021–30
16 Table 3: Marketed drugs for ADHD
23 Table 4: Pipeline drugs for ADHD in the US
27 Table 5: SPN-812 for ADHD (December 22, 2020)
29 Table 6: ABV-1504 for ADHD (November 9, 2020)
30 Table 7: SPN-812 for ADHD (November 9, 2020)
31 Table 8: AR19 for ADHD (October 8, 2020)
32 Table 9: AR19 for ADHD (October 6, 2020)
33 Table 10: AR19 for ADHD (September 10, 2020)
39 Table 11: Historical global sales, by drug ($m), 2016–20
40 Table 12: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!